Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)
Status and phase
Conditions
Treatments
Details and patient eligibility
About
Avastin is a novel antiangiogenic agent that has recently been shown to improve response rates and survival of patients with advanced nonsquamous non-small cell lung cancer when added to front-line carboplatin/paclitaxel chemotherapy, and is now being routinely incorporated into the treatment of these patients. Alimta is a recently approved chemotherapeutic that has shown activity against non-small cell lung cancer when given alone and in combination with carboplatin, has a favorable toxicity profile andrequires only a brief (10 minute) infusion time. Therefore we propose to study the combination of Avasin, Alimta, and Carboplatin administered as front-line therapy to patients with advanced nonsquamous non-small cell lung cancer.
Sex
Ages
Volunteers
Inclusion criteria
I am 18 years of age or older. I have advanced non-small lung cancer. I have not had any major surgical procedures within 28 days prior to my starting treatment.
I have high blood pressure that is controlled. I am not on heparin, coumadin or lovonox for treatment of medical conditions. I do not have serious wound healing problems. I have not received any previous treatment, except radiation therapy for my disease.
Exclusion criteria
Trial design
Primary purpose
Allocation
Interventional model
Masking
Trial contacts and locations
Loading...
Central trial contact
Elta Field
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal